Hypoxia-activated prodrug evofosfamide treatment in pancreatic ductal adenocarcinoma xenografts alters the tumor redox status to potentiate radiotherapy

S Kishimoto, JR Brender… - Antioxidants & Redox …, 2021 - liebertpub.com
Aims: In hypoxic tumor microenvironments, the strongly reducing redox environment
reduces evofosfamide (TH-302) to release a cytotoxic bromo-isophosphoramide (Br-IPM) …
被引用次数：32 相关文章

Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy

S Kishimoto, JR Brender… - … & redox signaling, 2021 - pubmed.ncbi.nlm.nih.gov
Aims: In hypoxic tumor microenvironments, the strongly reducing redox environment
reduces evofosfamide (TH-302) to release a cytotoxic bromo-isophosphoramide (Br-IPM) …

Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.

S Kishimoto, JR Brender… - Antioxidants & Redox …, 2020 - europepmc.org
Aims: In hypoxic tumor microenvironments, the strongly reducing redox environment
reduces evofosfamide (TH-302) to release a cytotoxic bromo-isophosphoramide (Br-IPM) …

[引用][C] Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate …

S Kishimoto, JR Brender, GVR Chandramouli… - Antioxidants & Redox …, 2021 - cir.nii.ac.jp
Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma
Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy | CiNii Research CiNii …
[PDF] researchgate.net

[PDF][PDF] Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate …

S Kishimoto, JR Brender, GVR Chandramouli, Y Saida… - researchgate.net
Aims: In hypoxic tumor microenvironments, the strongly reducing redox environment
reduces evofosfamide (TH-302) to release a cytotoxic bromo-isophosphoramide (Br-IPM) …
[HTML] nih.gov

[HTML][HTML] Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate …

S Kishimoto, JR Brender… - Antioxidants & Redox …, 2021 - ncbi.nlm.nih.gov
Aims: In hypoxic tumor microenvironments, the strongly reducing redox environment
reduces evofosfamide (TH-302) to release a cytotoxic bromo-isophosphoramide (Br-IPM) …

Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.

S Kishimoto, JR Brender… - Antioxidants & Redox …, 2020 - europepmc.org
Aims: In hypoxic tumor microenvironments, the strongly reducing redox environment
reduces evofosfamide (TH-302) to release a cytotoxic bromo-isophosphoramide (Br-IPM) …